Correction: Mani et al. Bioassay Guided Fractionation Protocol for Determining Novel Active Compounds in Selected Australian Flora. 2022, , 2886.

In the original publication [...

Synergistic optimization of thermoelectric properties in CuNiSnSe composited with CuO nanoparticles.

Quaternary chalcogenides have gained significant attention in thermoelectric (TE) material research for their high thermoelectric conversion efficiency. The present work investigates the optimisation of the thermoelectric performance of CuNiSnSe utilising the energy filtering effect through the incorporation of CuO into a host matrix. The impact of varying the weight percentage of CuO on the TE properties of the nanocomposite materials was studied and compared with that of pristine CuNiSnSe.

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti-PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a first-in-human, phase 1 study (NCT03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies.

Patients And Methods: Adult patients received 1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks (Q3W) across various dose-escalation schedules.

Severe Anaphylaxis From Remimazolam in a Mastocytosis Cancer Patient: A Case Report.

Remimazolam besylate is a novel, rapid-onset, ultra-short-acting benzodiazepine with an advantageous cardio-respiratory safety profile. To date, there have been few published reports of remimazolam-induced anaphylaxis, none of which are documented in patients with mast cell disease. We describe the case of a 77-year-old male with oncologic mastocytosis who developed anaphylaxis following remimazolam administration.